Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Asset disposition
Acq. announced
Director departure
|
|
Gene Biotherapeutics, Inc. (CRXM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/03/2023 |
SC 13G/A
| Jemapete Christopher J reports a 6.2% stake in GENE BIOTHERAPEUTICS, INC. |
| 01/04/2018 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/05/2017 |
SC 13G/A
| SABBY MANAGEMENT, LLC reports a 10% stake in Taxus Cardium Pharmaceuticals Group, Inc. |
| 01/05/2016 |
SC 13G/A
| SABBY MANAGEMENT, LLC reports a 10% stake in Taxus Cardium Pharmaceuticals Group, Inc. |
| 01/08/2015 |
SC 13G/A
| SABBY MANAGEMENT, LLC reports a 10% stake in Taxus Cardium Pharmaceuticals Group, Inc. |
| 01/08/2014 |
SC 13G/A
| SABBY MANAGEMENT, LLC reports a 10% stake in Cardium Therapeutics, Inc. |
| 03/05/2013 |
SC 13G/A
| SABBY MANAGEMENT, LLC reports a 7.4% stake in Cardium Therapeutics, Inc. |
|
|